Sugi Predict

Sugi Predict / Compounds / SCHEMBL2429992

SCHEMBL2429992

SCHEMBL2429992

O=C1CCCc2ccc(Br)cc2N1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 2/20 0.66
▸ AHR P35869 2/20 0.66
▸ MAPT P10636 1/20 0.58
▸ MAOA P21397 3/20 0.50
▸ MAOB P27338 3/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ IDO1 P14902 1/20 0.48
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ NPC1 O15118 3/20 0.45
▸ TDP2 O95551 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ MAPK13 O15264 1/20 0.43
▸ MAPK12 P53778 1/20 0.43
▸ MAPK11 Q15759 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ KIF11 P52732 1/20 0.42
▸ CRBN Q96SW2 1/20 0.41
▸ PARP1 P09874 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29638042 1.00 CMA1 (0.66) CMA1AHRMAPTMAOAMAOB
SCHEMBL29754270 0.89 CMA1 (0.70) CMA1AHRMAPTMAOAMAOB
SCHEMBL2220942 0.89 CMA1 (0.70) CMA1AHRMAPTMAOAMAOB
SCHEMBL3627854 0.86 IDO1 (0.58) CMA1AHRMAPTMAOAMAOB
SCHEMBL30320568 0.86 IDO1 (0.58) CMA1AHRMAPTMAOAMAOB
SCHEMBL4891129 0.82 IDO1 (0.54) CMA1AHRMAPTMAOAMAOB
SCHEMBL7505614 0.80 MAPT (0.59) CMA1AHRMAPTCA9MEN1
SCHEMBL29584808 0.79 AHR (1.00) CMA1AHRMAPTMAOAMAOB
SCHEMBL19982 0.79 AHR (1.00) CMA1AHRMAPTMAOAMAOB
SCHEMBL9025047 0.79 MAPT (0.58) CMA1AHRMAPTMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US claimed
US-20250368633-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF ARTIVILA BIOPHARMA (CN) 2025-12-04 — — US disclosed
EP-4582414-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF Artivila Biopharma (CN) 2025-07-09 — — EP disclosed
EP-3917527-B1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-04-23 — — EP disclosed
CN-113645971-B Compounds and uses thereof 福宏治疗公司 2024-10-18 — — CN disclosed
CN-117320754-A Prostatitis treatment 北京生命科学研究所 2023-12-29 — — CN disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 — — US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 — — US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 — — US disclosed
US-20230079819-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-16 — — US disclosed
US-7799933-B2 Sulfonamide derivatives HOFFMAN-LA ROCHE INC. (US) 2010-09-21 — — US disclosed
EP-2097373-B1 SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) HOFFMANN LA ROCHE (CH) 2010-08-11 — — EP disclosed
US-20100160291-A1 TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-06-24 — — US disclosed
US-7713996-B2 Indolyl derivatives which are L-CPT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2010-05-11 — — US disclosed
EP-2097373-A1 SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) F. Hoffmann-Roche AG (CH) 2009-09-09 — — EP disclosed
US-20080153805-A1 SULFONAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-06-26 — — US disclosed
WO-2008074692-A1 SULFONAMIDE DERIVATIVES AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTL ) F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 — — WO disclosed
EP-1926711-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 — — EP disclosed
WO-2007031429-A1 NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 — — WO disclosed
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060567-A1 Novel indolyl derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 CMA1 2199/4885AHR 1070/4885MAPT 1807/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL CMA1 3517/4885AHR 4622/4885MAPT 2293/4885
US-20100160291-A1 TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS OPRK1, SCN3A, CACNA1A CMA1 3486/4885AHR 2212/4885MAPT 681/4885
US-20080153805-A1 SULFONAMIDE DERIVATIVES CPT1A, SULT2A1, SULT1A1 CMA1 1385/4885AHR 2601/4885MAPT 3396/4885
US-20230079819-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB CMA1 4023/4885AHR 2619/4885MAPT 2074/4885
US-20250368633-A1 AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF RIPK1, RIPK2, RIPK4 CMA1 1971/4885AHR 3874/4885MAPT 2894/4885
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL CMA1 3239/4885AHR 4/4885MAPT 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.